Barclays
SLNO

Barclays’s Soleno Therapeutics SLNO Stock Holding History

Barclays’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-28,400
Closed -$1.92M – 5642
2025
Q3 		$1.92M Buy
+28,400
New +$2.11M ﹤0.01% 2919
2025
Q2 		– Sell
-10,000
Closed -$715K – 5517
2025
Q1 		$715K Buy
+10,000
New +$487K ﹤0.01% 3301

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return

Barclays's SLNO Position: Q1 2026 in Review

Barclays reduced its Soleno Therapeutics (SLNO) stake by 66% in Q1 2026, selling an estimated $4.06M and leaving 54,219 shares worth $1.82M. The position accounts for ﹤0.01% of the portfolio, ranked #2414.

Barclays first reported a position in SLNO in Q2 2020 and has held it in 16 quarters since. The position peaked at $11.6M in Q2 2025. 225 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

  • Barclays held 54,219 shares of Soleno Therapeutics worth $1.82M as of Q1 2026.
  • Barclays sold 103,466 Soleno Therapeutics shares in Q1 2026, an estimated $4.06M.
  • Soleno Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2414 holding.
  • Barclays first reported a position in Soleno Therapeutics in Q2 2020 and has held it in 16 quarters since.
  • Barclays's Soleno Therapeutics position peaked at $11.6M in Q2 2025.
  • 225 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.